Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | TKT | P29401 | 4/20 | 0.36 |
| ▸ | PDXK | O00764 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.34 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14810588 | 0.79 | YTHDC1 (0.40) | KDM4EALDH1A1HPGDHSD17B10PDXK | |
| SCHEMBL1521589 | 0.77 | HTT (0.51) | KDM4EALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL2120597 | 0.75 | KDM4E (0.48) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL3820985 | 0.74 | HTT (0.49) | KDM4EALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL27911502 | 0.74 | KDM4E (0.47) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| Lithium Ion SCHEMBL3820982 | 0.73 | HTT (0.48) | KDM4EALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL12586215 | 0.73 | NUDT1 (0.35) | HSD17B10LMNA | |
| SCHEMBL479344 | 0.72 | LMNA (0.61) | KDM4EALDH1A1LMNATKTHSP90AA1 | |
| SCHEMBL15211577 | 0.72 | PDXK (0.46) | AGTR1AGTR2KDM4EALDH1A1HPGD | |
| SCHEMBL18181689 | 0.71 | AURKA (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10000490-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170253593-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-09-07 | — | — | US | disclosed |
| US-9732065-B2 | Cyclic aminomethyl pyrimidine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-9732065-B2 | Cyclic aminomethyl pyrimidine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-9732065-B2 | Cyclic aminomethyl pyrimidine derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2017-08-15 | — | — | US | disclosed |
| US-9695165-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-03-09 | — | — | US | disclosed |
| US-9340514-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2016-05-17 | — | — | US | disclosed |
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-05-05 | — | — | US | disclosed |
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2016-05-05 | — | — | US | disclosed |
| EP-3006438-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2016-04-13 | — | — | EP | disclosed |
| EP-3006438-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | Sumitomo Dainippon Pharma Co., Ltd. (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-9126951-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150210694-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
| US-20150197519-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2015-07-16 | — | — | US | disclosed |
| US-20140378481-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-12-25 | — | — | US | disclosed |
| WO-2014192868-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | 大日本住友製薬株式会社 (JP) | 2014-12-04 | — | — | WO | disclosed |
| US-8802697-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140088100-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210694-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | AGTR1 785/4885AGTR2 767/4885KDM4E 2039/4885 |
| US-20140378481-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | AGTR1 785/4885AGTR2 767/4885KDM4E 2039/4885 |
| US-20170253593-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | AGTR1 1109/4885AGTR2 925/4885KDM4E 748/4885 |
| US-20140088100-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | AGTR1 785/4885AGTR2 767/4885KDM4E 2039/4885 |
| US-10000490-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR4, FGFR1, FGFR2 | AGTR1 1109/4885AGTR2 925/4885KDM4E 748/4885 |
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | AGTR1 785/4885AGTR2 767/4885KDM4E 2039/4885 |
| US-20160122319-A1 | CYCLIC AMINOMETHYL PYRIMIDINE DERIVATIVE | DRD2, DRD4, DRD1 | AGTR1 28/4885AGTR2 40/4885KDM4E 1245/4885 |
| US-20150197519-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR4, FGFR1, FGFR2 | AGTR1 1109/4885AGTR2 925/4885KDM4E 748/4885 |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | AGTR1 785/4885AGTR2 767/4885KDM4E 2039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.